title: Resveratrol-loaded nanoparticles based on poly(epsilon-caprolactone) and poly(D,L-lactic-co-glycolic acid)-poly(ethylene glycol) blend for prostate cancer treatment.
abstract: Nanoencapsulation of antiproliferative and chemopreventive phytoalexin trans-resveratrol (RSV) is likely to provide protection against degradation, enhancement of bioavailability, improvement in intracellular penetration and control delivery. In this study, polymeric nanoparticles (NPs) encapsulating RSV (nano-RSV) as novel prototypes for prostate cancer (PCa) treatment were designed, characterized and evaluated using human PCa cells. Nanosystems, composed of a biocompatible blend of poly(epsilon-caprolactone) (PCL) and poly(d,l-lactic-co-glycolic acid)-poly(ethylene glycol) conjugate (PLGA-PEG-COOH), were prepared by a nanoprecipitation method, and characterized in terms of morphology, particle size and zeta potential, encapsulation efficiency, thermal analyses, and in vitro release studies. Cellular uptake of NPs was then evaluated in PCa cell lines DU-145, PC-3, and LNCaP using confocal fluorescence microscopy, and antiproliferative efficacy was assessed using MTT assay. With encapsulation efficiencies ranging from 74% to 98%, RSV was successfully loaded in PCL:PLGA-PEG-COOH NPs, which showed an average diameter of 150 nm. NPs were able to control the RSV release at pH 6.5 and 7.4, mimicking the acidic tumoral microenvironment and physiological conditions, respectively, with only 55% of RSV released within 7 h. In gastrointestinal simulated fluids, NPs released about 55% of RSV in the first 2 h in acidic medium, and their total RSV content within the subsequent 5 h at pH 7.4. Confocal fluorescence microscopy observations revealed that NPs were efficiently taken up by PCa cell lines. Furthermore, nano-RSV significantly improved the cytotoxicity compared to that of free RSV toward all three cell lines, at all tested concentrations (from 10 μM to 40 μM), proving a consistent sensitivity toward both the androgen-independent DU-145 and hormone-sensitive LNCaP cells. Our findings support the potential use of developed nanoprototypes for the controlled delivery of bioactive RSV for PCa chemoprevention/chemotherapy.
authors: Department of Chemistry and Pharmacy, Laboratory of Nanomedicine, University of Sassari , 07100 Sassari, Italy.
authors: Vanna
authors: V
authors: Sanna
authors: Imtiaz Ahmad
authors: IA
authors: Siddiqui
authors: Mario
authors: M
authors: Sechi
authors: Hasan
authors: H
authors: Mukhtar
mesh_terms: D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D006801:Humans; D009682:Magnetic Resonance Spectroscopy; D008297:Male; D008855:Microscopy, Electron, Scanning; D008856:Microscopy, Fluorescence; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D011091:Polyesters / Q000737:chemistry*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D000077185:Resveratrol; D017550:Spectroscopy, Fourier Transform Infrared; D013267:Stilbenes / Q000008:administration & dosage / Q000737:chemistry* / Q000627:therapeutic use*
chemical_list: D011091:Polyesters; D013267:Stilbenes; C016240:polycaprolactone; D000077185:Resveratrol
references: Int J Pharm. 2003 Aug 27;262(1-2):1-11
references: 12927382
references: Recent Pat Cardiovasc Drug Discov. 2007 Jun;2(2):133-8
references: 18221111
references: Int J Nanomedicine. 2012;7:591-605
references: 22346353
references: J Control Release. 2012 Jul 20;161(2):505-22
references: 22353619
references: Clin Cancer Res. 2007 Mar 1;13(5):1611-9
references: 17332308
references: Clin Pharmacol Ther. 2008 May;83(5):761-9
references: 17957183
references: Cancer Res. 1999 Dec 1;59(23):5892-5
references: 10606230
references: Mol Pharm. 2012 Sep 4;9(9):2365-79
references: 22823097
references: Carcinogenesis. 2008 Oct;29(10):2001-10
references: 18586690
references: Biomaterials. 2007 Feb;28(5):869-76
references: 17055572
references: Cancer Res. 2001 Feb 15;61(4):1604-10
references: 11245472
references: J Nutr Biochem. 2005 Aug;16(8):449-66
references: 16043028
references: Pharm Res. 2010 Jun;27(6):1054-60
references: 20221894
references: Exp Cell Res. 1999 May 25;249(1):109-15
references: 10328958
references: Adv Drug Deliv Rev. 2011 Mar 18;63(3):170-83
references: 20965219
references: Cancer Res. 2010 Dec 1;70(23):9755-64
references: 20952510
references: Maturitas. 2012 Sep;73(1):27-32
references: 22341739
references: Mol Biotechnol. 2013 Sep;55(1):78-86
references: 23371307
references: Int J Oncol. 1999 Aug;15(2):245-52
references: 10402233
references: Cancer Res. 2004 Jan 15;64(2):696-703
references: 14744787
references: Biomaterials. 2003 Feb;24(4):629-38
references: 12437957
references: J Control Release. 2002 Jul 18;82(1):105-14
references: 12106981
references: Cancer Lett. 2002 Jan 25;175(2):165-73
references: 11741744
references: Ann N Y Acad Sci. 2011 Jan;1215:103-8
references: 21261647
references: J Med Chem. 2011 Mar 10;54(5):1321-32
references: 21306166
references: Antioxid Redox Signal. 2009 Nov;11(11):2851-97
references: 19432534
references: Int J Pharm. 2006 Jan 3;307(1):93-102
references: 16303268
references: Cancer Lett. 2003 Feb 20;190(2):157-63
references: 12565170
references: Nanoscale Res Lett. 2011 Mar 28;6(1):260
references: 21711774
references: Biochem Soc Trans. 2010 Feb;38(Pt 1):50-3
references: 20074034
references: J Biomed Mater Res A. 2009 Oct;91(1):263-76
references: 18980197
references: Int J Nanomedicine. 2012;7:4391-408
references: 22927757
references: Adv Drug Deliv Rev. 2008 Dec 14;60(15):1615-26
references: 18840489
references: Mol Cancer Ther. 2004 Nov;3(11):1355-64
references: 15542774
references: FASEB J. 2002 Aug;16(10):1217-26
references: 12153989
references: Curr Drug Deliv. 2007 Jul;4(3):185-93
references: 17627492
references: Blood. 2003 Aug 1;102(3):987-95
references: 12689943
references: Cancer Res. 2001 Jun 15;61(12):4731-9
references: 11406544
references: Cancer Res. 2009 Mar 1;69(5):1712-6
references: 19223530
references: Int J Pharm. 2004 Jun 18;278(1):1-23
references: 15158945
references: Asian Pac J Cancer Prev. 2008 Jan-Mar;9(1):7-14
references: 18439064
references: J Pharm Sci. 1983 Oct;72(10):1189-91
references: 6644570
references: Colloids Surf B Biointerfaces. 2009 Aug 1;72(1):40-7
references: 19395246
references: Cancer Lett. 2013 Jun 28;334(1):142-51
references: 23201598
references: Carcinogenesis. 2006 May;27(5):1038-46
references: 16338953
references: Int J Nanomedicine. 2012;7:5501-16
references: 23093904
references: Nanomedicine. 2012 Sep;8 Suppl 1:S31-6
references: 22640911
references: Cell. 2012 Feb 3;148(3):387-9
references: 22304906
references: Nat Rev Cancer. 2011 Mar;11(3):211-8
references: 21326325
references: Cancer Res. 2002 May 1;62(9):2488-92
references: 11980638
references: Cancer Biother Radiopharm. 2010 Aug;25(4):471-7
references: 20735207
references: J Control Release. 2012 Mar 10;158(2):182-93
references: 21978644
references: Science. 1994 Mar 18;263(5153):1600-3
references: 8128245
references: Eur J Pharmacol. 2010 Sep 25;643(2-3):170-9
references: 20599920
references: Science. 1997 Jan 10;275(5297):218-20
references: 8985016
references: Int J Nanomedicine. 2013;8:747-65
references: 23459088
references: Urol Oncol. 2002 Nov-Dec;7(6):223-7
references: 12504842
references: Mol Nutr Food Res. 2005 May;49(5):377-95
references: 15830334
references: Int J Pharm. 2002 Oct 1;245(1-2):83-91
references: 12270245